Recruiting
Phase 1
Phase 2

EYC-0305

Sponsor:

Eyconis INC.

Code:

NCT07587515

Conditions

Neovascular (Wet) Age-Related Macular Degeneration

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

EYC-0305

Study Details

Brief summary:

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Conditions

Neovascular (Wet) Age-Related Macular Degeneration

Study ID

NCT07587515

Start date

May 19, 2026

Status verified date

Jun, 2026

Completion date

May, 2028

Anticipated

Primary completion date

May, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed informed consent

Exclusion Criteria:

  • Known hypersensitivity or known allergy that would preclude study drug administration
  • Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
  • Uncontrolled diabetes mellitus
  • History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
  • Renal failure, dialysis, or history of renal transplant
  • Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
  • Pregnant or breastfeeding women

Study Design

Enrollment

30 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: EYC-0305 Dose Level 1

experimental: EYC-0305 Dose Level 2

experimental: EYC-0305 Dose Level 3

experimental: EYC-0305 Dose Level 4

Interventions

EYC-0305

Extended-delivery anti-VEGF

Primary outcome measure

  • Incidence and severity of ocular treatment-emergent adverse events (TEAEs) [ Time Frame: Week 72 ]
  • Incidence and severity of systemic treatment-emergent adverse events (TEAEs) [ Time Frame: Week 72 ]

Central Contacts and Locations

Central contacts

Kim Reed, OD, FAAO

1-866-392-6647info@eyconis.com

Karen Chu, MS

1-866-392-6647info@eyconis.com

Locations

Beverly Hills, CA

Recruiting

Beverly Hills, California, United States, 90211

Wake Forest, NC

Recruiting

Wake Forest, North Carolina, United States, 27587

Erie, PA

Recruiting

Erie, Pennsylvania, United States, 16505

Bellaire, TX

Recruiting

Bellaire, Texas, United States, 77401

McAllen, TX

Recruiting

McAllen, Texas, United States, 78503

The Woodlands, TX

Recruiting

The Woodlands, Texas, United States, 77384

More Information

Sponsor

Eyconis INC.

Last update posted

Jul 7, 2026

Last verified

Jun, 2026

Keywords

  • EYC-0305
  • TransCon aVEGF
  • wet AMD
  • neovascular AMD
  • treatment naive
  • Eyconis
  • anti-VEGF

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Eyconis INC. on 2026-07-07.